US agency accuses L'Oreal of misleading marketing
September 12, 2012 in Medications
US regulators accused French cosmetics giant L'Oreal of misleading claims in marketing its Lancome line of anti-aging products, according to a letter released Tuesday.
In the letter, addressed to the president of L'Oreal-owned Lancome USA, the Food and Drug Administration said some Lancome products advertised online carry claims that "are intended to affect the structure or any function of the human body, rendering them drugs" under US law.
The products under scrutiny include the Genifique Youth Activating Concentrate, which claims to boost "the activity of genes and stimulates the production of youth proteins," according to the letter.
Another singled out is the Genifique Repair Youth Activating Night Cream, which claims to boost "the activity of genes."
Lancome has 15 days to respond to the FDA warning with specific steps it has taken to correct the violations, according to the letter dated Friday.
"We request that you take prompt action to correct all violations associated with your products, including the violations identified in this letter," wrote the FDA's Michael W. Roosevelt of the Center for Food Safety and Applied Nutrition. "Failure to do so may result in enforcement action without further notice."
L'Oreal is the world's largest cosmetics maker.
(c) 2012 AFP
-
EBay wins court fight against L'Oreal in UK
May 22, 2009 |
not rated yet |
0
-
FDA cracking down on fat-melting injections
Apr 07, 2010 |
not rated yet |
0
-
FDA cites claims on 2 green tea beverages
Sep 07, 2010 |
not rated yet |
0
-
Cosmetics may contain harmful particles
May 05, 2006 |
not rated yet |
0
-
Johnson & Johnson gets FDA warning on marketing
Aug 24, 2010 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
How can there be a term called "intestinal metaplasia" of stomach
14 hours ago
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
-
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013
-
Alcohol and acetaminophen
May 13, 2013
- More from Physics Forums - Medical Sciences
More news stories
New sleeping pill poised to hit US markets
An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.
Medications
3 hours ago |
5 / 5 (1) |
0
Global recommendations on child medicine
Transparent information on the evidence supporting global recommendations on paediatric medicines should be easily accessible in order to help policy makers decides on what drugs to include in their national drug lists, according ...
Medications
4 hours ago |
not rated yet |
0
Analgesics prescribed more heavily to women than to men, study finds
Regardless of pain, social class or age, a woman is more likely to be prescribed pain-relieving drugs. A study published in Gaceta Sanitaria (Spanish health scientific journal) affirms that this phenomenon is inf ...
Medications
12 hours ago |
not rated yet |
0
Breakup of physician, drug company relationship could improve health care, cut cost
A new report suggests that improved health care and significant reductions in drug costs might be attained by breaking up the age-old relationship between physicians and drug company representatives who promote the newest, ...
Medications
May 20, 2013 |
5 / 5 (1) |
0
FDA has safety concerns on Merck insomnia drug
Federal health regulators say an experimental insomnia drug from Merck can help patients fall asleep, but it also carries worrisome side effects, including daytime drowsiness and suicidal thinking.
Medications
May 20, 2013 |
not rated yet |
0
If you can remember it, you can remember it wrong
(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...
B vitamins could delay dementia
(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...
Reducing caloric intake delays nerve cell loss
Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...
Antidepressant reduces stress-induced heart condition
A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.
Insight into the dazzling impact of insulin in cells
Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.
Changing cancer's environment to halt its spread
By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces ...
